Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Aripiprazole OSF vs Abilify in Healthy Volunteers
NCT02501109Phase 1Completed
- Sponsor
- CMG Pharmaceutical Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of aripiprazole in schizophrenia (3 arms), sponsored by CMG Pharmaceutical Co., Ltd. Primary endpoint: Rate and extent of absorption (AUC, Cmax) at 28 days. Started Oct 2015; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02501109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501109.